Lucid Diagnostics Announces New Real-World Data Confirming EsoGuard's Utility As Non-Invasive Triage Tool; Increases Positive Yield Of Invasive Upper Endoscopy For Detection Of Esophageal Precancer And Cancer By 2.4-Fold
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics has announced new real-world data confirming the utility of its EsoGuard test as a non-invasive triage tool. The data shows that EsoGuard increases the positive yield of invasive upper endoscopy for detecting esophageal precancer and cancer by 2.4-fold.
August 06, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics' new data confirms the effectiveness of its EsoGuard test, which increases the positive yield of invasive upper endoscopy for detecting esophageal precancer and cancer by 2.4-fold.
The new data supports the effectiveness of Lucid Diagnostics' EsoGuard test, which is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100